This statement provides guidance on contraceptive choices for transgender and non-binary people and their partners, who are engaging in vaginal sex where there is a risk of pregnancy. The statement also offers general sexual health advice for these groups.
This statement summarises the available evidence regarding how contraception may affect a woman’s weight and how a woman’s weight may affect contraceptive efficacy. Looking at each method individually, the CEU advises clinicians on what proven and theoretical associations exist between contraception and weight.
This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.
Change of UKMEC category for use of progestogen-only injectable contraception by women at high risk of HIV infection from UKMEC1 to UKMEC2
A short documentary hosted on the Guardian website highlights some fatal cases of venous thrombosis that were associated with use of combined hormonal contraception.
A recently published multinational trial reports no pregnancies among 311 women who extended use of their existing Nexplanon® to four years and 204 women who continued to five years of use.[
This statement is a CEU response to a study published in JAMA Psychiatry titled Association of Hormonal Contraception with Depression.
Updated Document - Please note, this document was updated in September 2016. The previous version was published in August 2016.
After reviewing the available body of evidence, the Centers for Disease Control (CDC) in the USA have concluded that a causal relationship exists between prenatal Zika virus infection and microcephaly and other serious brain anomalies. Cases of locally-transmitted Zika virus are still being reported in Brazil and most of its neighbouring countries.
This statement is a CEU response to a study published in the BMJ titled Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.